EGFR and central nervous system cancer: It has been recently shown that EGFR inhibitors trigger adaptive responses through a TNF–JNK–Axl–ERK signaling axis in glioma cells.36 In a molecularly heterogeneous disease like GBM, this is likely but one of the many cellular and microenvironment dependent adaptive response mechanisms that occurs in response to EGFR inhibition.